Why Investors Should Care About MindMed’s LSD Trial for Anxiety
MindMed will present preliminary results from a Phase 2a study treating Generalized Anxiety Disorder with LSD therapy next month.
lsd
Psychedelic Business Spotlight – April 8
This week in psychedelic business news: Field Trip Health secures a patent; Core One Labs seeks more retail investors; a new CEO takes over GABA Therapeutics.
5 Most Important Psychedelic Clinical Trials in 2022
Here’s why we think MAPS’ second Phase 3 MDMA trial is the most important psychedelic study of 2022, and 4 more that may have huge impacts.
5 Mind-Bending Psychedelic Movies to Stream Right Now
Skip the drugs, and take a trip on the screen instead.
Psychedelic Researchers Doubt Microdosing in New York Times
After a disappointing microdosing study, Dr. Michiel van Elk says the trend is “just not that interesting.”
Is Wall Street the Next Stop for Psychedelics? Investing in the Psychedelic Medicine Sector
Elemental Advisors Inc. CEO Tim Collins paints a picture of the past, present, and future of the psychedelics market in this guest blog.
Is There a Difference Between Tripping on LSD and Psilocybin?
A double-blinded, randomized, and placebo-controlled study compares the subjective and autonomic effects of both psychedelics.
LSD Microdosing Study Finds ‘No Residual Effects’ on Mood or Cognition
Another study concludes with results challenging the increasingly popular narrative that microdosing psychedelics improves mood and cognitive function.
Psychedelic Business Spotlight – February 4
Levitee Labs Announces Interim CEO and Board of Directors Shuffle…
How to Prepare for Your First Psychedelic Trip in 5 Easy Steps
Psilocybin and LSD are becoming more popular and more accessible, but before your first psychedelic trip, it is essential to prepare.
End of content
End of content